Intranasal Sendai Virus Vaccination of Seropositive Children 1 to 2 Years of Age in a Phase I Clinical Trial Boosts Immune Responses Toward Human Parainfluenza Virus Type 1

Vaccines, Год журнала: 2025, Номер 13(4), С. 430 - 430

Опубликована: Апрель 19, 2025

Human parainfluenza virus type 1 (hPIV-1) is a major cause of serious respiratory diseases in young children. Annually, hPIV-1 results approximately 10,000 hospitalizations the United States due to croup, bronchiolitis, and/or pneumonia, and deaths worldwide acute lower tract infections among children less than 5 years age. Despite burden disease, no vaccine for currently approved. Sendai (SeV) murine PIV-1. It has structural similarities with under clinical development as an Jennerian vaccine. Attributes SeV include following: (a) needleless delivery, (b) rapid durable serum antibody responses after single intranasal administration, (c) IgG IgA nasal mucosa, (d) use platform recombinant vaccines against multiple pediatric pathogens. Evaluation tolerability, safety, immunogenicity healthy adults seropositive 3 6 age was previously conducted supported advancement evaluation younger Three 2 received dose × 105 EID50 (SENDAI, Clinicaltrials.gov NCT00186927). Adverse events were collected 28 days post-vaccine administration using diary cards participants followed six months total. Sera longitudinally laboratory virus-specific tests. Nasal swabs mucosal Intranasal well tolerated, only mild grade 1-2 that resolved spontaneously. No adverse events, medically attended or causing protocol termination reported. One participant had positive inoculated during first week vaccination. Although measurable PIV-1-specific antibodies at baseline, vaccination resulted significant increases all participants. Similarly, there levels Elevated persisted through follow-up. tolerated uniformly immunogenic Results encourage further SeV-based recombinants potential prevention infection by other

Язык: Английский

Protecting the next generation: how maternal Respiratory Syncytial Virus (RSV) vaccination during pregnancy safeguards child health

Revista Brasileira de Saúde Materno Infantil, Год журнала: 2025, Номер 25

Опубликована: Янв. 1, 2025

Язык: Английский